A Deeper Look into Novel Potassium
Binders in the Management of Hyperkalemia with End Stage Renal
Disease: Individualizing Treatment for Improved Clinical and Cost
A continuing medical education
activity provided by NAMCP and AAMCN
Therapeutic Advances in the Management of Hyperkalemia with End
Renal Disease: Improving Clinical and Cost Outcomes in an Evolving
Treatment Paradigm is a three-part webinar series.
This is Part 1 of the series focusing on the management of
patients with End Stage Renal Disease.
This activity is an archive from the webinar held October 21, 2020
This activity is valid from November 1, 2020 to November 1, 2022
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
Hyperkalemia, also known has high potassium, is an elevated level of
potassium in the blood. Typically this results in no symptoms, but
occasionally when severe it results in palpitations, muscle pain,
muscle weakness, or numbness. Decreased kidney function is a major
cause of hyperkalemia, especially in chronic kidney disease (CKD).
Hyperkalemia occurs in up to 10% of hospitalized patients and is
associated increased morbidity if left unaddressed. Fortunately for
patients who experience hyperkalemia, new therapies have become
available in recent years that have shown improved efficacy and
safety. Attendees will be updated on these novel options and how
they can integrate them into the treatment paradigm and optimize
Upon completion of this
activity, participants will be able to:
Analyze the clinical and economic
burden of hyperkalemia and the impact of suboptimal management
Identify the risk factors and
pathophysiologic mechanisms associated with the development of
hyperkalemia in key patient populations
Evaluate recent potassium binders in
terms of safety, efficacy, labeling, dosing and role in
hyperkalemia with end stage renal disease management strategies
Identify patients with hyperkalemia
with end stage renal disease who would potentially benefit from
a novel potassium binder therapy
||Javed Butler, MD, MBA,
Patrick A. Lehan Chair in Cardiovascular Research
Professor of Medicine and Physiology
University of Mississippi
serves as a consultant for Abbott, Adrenomed, Amgen,
Applied Therapeutics, Array, Astra Zeneca, Bayer,
Boehringer Ingelheim, CVRx, G3 Pharma, Impulse Dynamics,
Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck,
Novartis, NovoNordisk, Relypsa, Roche, Sequana Medical,
V-Wave Limited, and Vifor. His presentation has been
peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue